Urticaria News and Research

RSS
Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

SYNERA can help prevent needle stick pain associated with superficial IVs

SYNERA can help prevent needle stick pain associated with superficial IVs

Researchers identify target molecules for development of new allergy drugs

Researchers identify target molecules for development of new allergy drugs

Researchers identify several target molecules suitable for development of new allergy drugs

Researchers identify several target molecules suitable for development of new allergy drugs

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

FDA approves Xolair for treatment of chronic idiopathic urticaria

FDA approves Xolair for treatment of chronic idiopathic urticaria

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt announces commercial launch of PENNSAID

FDA approves New Drug Application for PENNSA 2%

FDA approves New Drug Application for PENNSA 2%

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Crealta to acquire all assets of Savient Pharmaceuticals

Crealta to acquire all assets of Savient Pharmaceuticals

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules